Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Avecho Biotechnology Ltd V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Comment by skibum45on May 21, 2018 10:55pm
69 Views
Post# 28061676

RE:Plan of Arrangement Materials - Buyout DD

RE:Plan of Arrangement Materials - Buyout DD
JohnnyTSX wrote: Have a look at Schedule E (Page E1) in the Plan of Arrangement book that show the 3 payexamples.

In particular, in order to pay out the whole $0.45c to AVE shareholders, DSKE would have to pay $27,096,737 CAD based on the shares out. The EBITDA required to make this payment is ~$27,900,000.  

This speaks to DSKE thinking one of two things, imho:

1) they won't make the EBITDA target of $18M ($15.9M in 2017)
2) they are going to blow it out of the water as shown in example #3 using $50,000,000 EBITDA.

Anything inbetween is sort of a wash and I don't think DSKE is acquiring AVE to "break even". 

I am growing pretty bullish on AVE growing its EBITDA in 2018/19 and thus bailing on AVE prior to arrangement deal might just be a mistake - even if it reaches $1.05-$1.10, imo. 

John.

Not sure if you listened to the DSKE conference call recently.  In discussing AVE, it really sounded to me that they expect to be paying the earnout, barring some unforseen negative surprise.  Seems like it's almost a foregone conclusion for them.

<< Previous
Bullboard Posts
Next >>